SCHEMBL4528153

SCHEMBL4528153

COc1ccc(CN(C)C)cc1N

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.67
HTR7 P34969 4/20 0.58
ALDH1A1 P00352 4/20 0.50
CYP3A4 P08684 2/20 0.50
HTR1A P08908 1/20 0.49
HTR1D P28221 1/20 0.49
HTR1B P28222 1/20 0.49
HTR2A P28223 1/20 0.49
HTR2C P28335 1/20 0.49
HTR1E P28566 1/20 0.49
HTR2B P41595 1/20 0.49
HTR3A P46098 1/20 0.49
HTR5A P47898 1/20 0.49
HTR6 P50406 1/20 0.49
MEN1 O00255 1/20 0.48
MAPT P10636 1/20 0.48
THRB P10828 1/20 0.48
KMT2A Q03164 1/20 0.48
AOC3 Q16853 1/20 0.45
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5913154 0.98 GAA (0.65) GAAHTR7ALDH1A1CYP3A4HTR1A
SCHEMBL30833064 0.85 ALDH1A1 (0.67) GAAHTR7ALDH1A1CYP3A4HTR1A
SCHEMBL1961585 0.85 ALDH1A1 (0.67) GAAHTR7ALDH1A1CYP3A4HTR1A
Hydrochloric Acid SCHEMBL27621161 0.84 ALDH1A1 (0.65) GAAHTR7ALDH1A1CYP3A4HTR1A
SCHEMBL5675706 0.82 HTR7 (0.64) HTR7ALDH1A1CYP3A4HTR1AHTR1D
SCHEMBL3716351 0.82 GAA (0.62) GAAHTR7ALDH1A1CYP3A4HTR1A
SCHEMBL5913873 0.82 HSD17B10 (0.50) GAAHTR7ALDH1A1MEN1MAPT
Hydrochloric Acid SCHEMBL5913770 0.81 USP2 (0.49) GAAHTR7ALDH1A1MEN1MAPT
SCHEMBL3720231 0.80 GAA (0.56) GAAALDH1A1CYP3A4MEN1MAPT
Hydrochloric Acid SCHEMBL5913692 0.80 GAA (0.44) GAAHTR7ALDH1A1HTR1AHTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103517903-B Pyrrolopyridine aminoderivative as MPS1 inhibitor 癌症研究科技有限公司 2017-03-01 CN disclosed
CN-103517903-A Pyrrolopyridineamino derivatives as MPS1 inhibitors CANCER REC TECH LTD 2014-01-15 CN disclosed
US-20090036474-A1 Quinazoline derivatives for use against cancer PLE PATRICK 2009-02-05 US disclosed
CN-101291924-A Isoindole-imide compounds and compositions comprising and methods of using the same CELGENE CORP (US) 2008-10-22 CN disclosed
EP-1802608-A1 QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER AstraZeneca AB (SE) 2007-07-04 EP disclosed
WO-2006040526-A1 QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER ASTRAZENECA AB (SE) 2006-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036474-A1 Quinazoline derivatives for use against cancer AQP3, AQP1, F12 GAA 3392/4885HTR7 606/4885ALDH1A1 2449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.